Risk of Prostate Cancer Reclassification Varies With Time

The rate of reclassification during surveillance is not equally distributed across time or risk groups. Due to misclassification at the time of diagnosis, the rates of reclassification between very-low-risk and low-risk groups are similar within the first two years but differ significantly beyond two years. The risk of reclassification falls over time with each non-reclassifying biopsy beyond two years. Read the article.

UroToday Introduces Advanced Prostate Cancer Treatment Video Channel

UroToday has expanded its video-on-demand content in the UrologyTUBE™ with a new video channel featuring multi-media lectures focusing on treatment of men with advanced prostate cancer. The new channel specifically focuses on androgen deprivation treatment (hormone treatment) as the backbone of advanced prostate cancer treatment. View the channel.  (Free UroToday login required.)  

More Evidence of Harm From Selenium in Prostate Cancer

A new analysis has found that men diagnosed with nonmetastatic prostate cancer who consumed more than 140 μg a day of supplemental selenium had over a two-and-a-half–fold excess risk for death from prostate cancer compared with nonsupplement users. On the other hand, there was a modest 12% inverse association between selenium supplementation and the risk for overall mortality (HR, 0.88) among men who took 140 μg of a selenium supplement or more per day compared with those who didn’t use supplements. Read the article.

Bipolar Androgen Therapy

Research hope for prostate cancer Pouring petrol on the fire can potentially reverse resistance to hormone treatments for prostate cancer, new research suggests. The counter-intuitive strategy called bipolar androgen therapy (BAT) involves boosting levels of the male hormone testosterone, which normally stimulates prostate cancer growth. In a small pilot study, scientists found that alternating high and low testosterone levels caused seven of 16 patients with resistant prostate cancer to go into remission. Read the article.

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique

High-dose-rate brachytherapy (HDR) is a method of conformal dose escalation to the prostate. It can be used as a local boost in combination with external beam radiotherapy, with a high degree of efficacy and low rate of long term toxicity. Data consistently reports relapse free survival rates of greater than 90% for intermediate risk patients and greater than 80% for high risk. Results are superior to those achieved with external beam radiotherapy alone. Read the article. (Free UroToday login required.)

Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes

Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa). Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score. Results. At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, …

Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes Read More »

Scroll to Top